Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study. Grégoire, N., Mbarga, D., Mirfendereski, H., Stanke-Labesque, F., Breilh, D., Forestier, E., Ferry, T., Goutelle, S., Gavazzi, G., Brunet, T., Paccalin, M., Roubaud-Baudron, C., the Infectiology, GInGer), G. I. (., Albaret, G., Hyernart, C., Thiel, E., Meriglier, E., Bronnimann, D., Blanc, P., Clabe, E., Domergue, H., Chaussade, H., Lartigau, M., Pavese, P., Pierre, I., Arlaud, C., Froidure, M., Le Marechal, M., Drevet, S., Allan, L., Bioteau, C., Pouderoux, C., Chabert, P., Gaujard, S., De La Gastine, B., Leperre, A., Chauleur, Y., Lanfranchi, G., Schir, S., Brunet, T., Gueremy, A., Bosch, A., Destrem, A., & Isnard, M. Journal of Antimicrobial Chemotherapy, November, 2025.
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study [link]Paper  doi  abstract   bibtex   1 download  
Abstract Background Amoxicillin/clavulanic acid (AMX/CLV) is commonly prescribed in older adults. Because oral and intravenous (IV) routes may be compromised by swallowing disorders or poor venous access, subcutaneous (SC) administration of AMX/CLV could be an alternative. The main objective of this study was to compare the bioavailability of AMX and CLV after IV and SC administration in older patients. Patients and methods This prospective multicentre study enrolled patients aged over 65 y receiving SC or IV AMX/CLV (1 g/0.2 g/8 h). At steady state, AMX and CLV concentrations were measured just before and after the infusion, at 2 h (in the SC group only) and at 5 h using liquid chromatography coupled to tandem mass spectrometry. Population PK analysis estimated SC AMX/CLV bioavailability in comparison to IV administration and tolerance was assessed. Results Seventeen patients (mean age 85.1 ± 4.8 y) were enrolled (14 in the IV group and three in the SC group). SC bioavailability of AMX and CLV was estimated at 78% and 82%, respectively. Although Cmax values were ∼45% lower with SC administration, unbound AMX concentrations remained above thresholds for common pathogens (i.e. Streptococcus pneumoniae, Enterococci and Enterobacterales) and trough concentrations were close to those observed after IV administration. On the basis of safety assessment after 122 IV and SC infusions, no serious adverse event related to the treatment occurred and local SC adverse events were transient oedema, erythema and pain. Conclusions The present study provides data supporting the use of SC administration of AMX/CLV in the older population.
@article{gregoire_evaluation_2025,
	title = {Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the {PhASAge} {Study}},
	copyright = {https://academic.oup.com/pages/standard-publication-reuse-rights},
	issn = {0305-7453, 1460-2091},
	url = {https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaf381/8321380},
	doi = {10.1093/jac/dkaf381},
	abstract = {Abstract 
             
              Background 
              Amoxicillin/clavulanic acid (AMX/CLV) is commonly prescribed in older adults. Because oral and intravenous (IV) routes may be compromised by swallowing disorders or poor venous access, subcutaneous (SC) administration of AMX/CLV could be an alternative. The main objective of this study was to compare the bioavailability of AMX and CLV after IV and SC administration in older patients. 
             
             
              Patients and methods 
              This prospective multicentre study enrolled patients aged over 65 y receiving SC or IV AMX/CLV (1 g/0.2 g/8 h). At steady state, AMX and CLV concentrations were measured just before and after the infusion, at 2 h (in the SC group only) and at 5 h using liquid chromatography coupled to tandem mass spectrometry. Population PK analysis estimated SC AMX/CLV bioavailability in comparison to IV administration and tolerance was assessed. 
             
             
              Results 
              Seventeen patients (mean age 85.1 ± 4.8 y) were enrolled (14 in the IV group and three in the SC group). SC bioavailability of AMX and CLV was estimated at 78\% and 82\%, respectively. Although Cmax values were ∼45\% lower with SC administration, unbound AMX concentrations remained above thresholds for common pathogens (i.e. Streptococcus pneumoniae, Enterococci and Enterobacterales) and trough concentrations were close to those observed after IV administration. On the basis of safety assessment after 122 IV and SC infusions, no serious adverse event related to the treatment occurred and local SC adverse events were transient oedema, erythema and pain. 
             
             
              Conclusions 
              The present study provides data supporting the use of SC administration of AMX/CLV in the older population.},
	language = {en},
	urldate = {2025-12-08},
	journal = {Journal of Antimicrobial Chemotherapy},
	author = {Grégoire, Nicolas and Mbarga, David and Mirfendereski, Hélène and Stanke-Labesque, Françoise and Breilh, Dominique and Forestier, Emmanuel and Ferry, Tristan and Goutelle, Sylvain and Gavazzi, Gaëtan and Brunet, Thomas and Paccalin, Marc and Roubaud-Baudron, Claire and {the Infectiology and Geriatrics InterGroup (SPILF-SFGG GInGer)} and Albaret, Guillaume and Hyernart, Caroline and Thiel, Elise and Meriglier, Etienne and Bronnimann, Didier and Blanc, Peggy and Clabe, Emilie and Domergue, Hélène and Chaussade, Hélène and Lartigau, Marion and Pavese, Patricia and Pierre, Isabelle and Arlaud, Cyprien and Froidure, Marie and Le Marechal, Marion and Drevet, Sabine and Allan, Laure and Bioteau, Catherine and Pouderoux, Cécile and Chabert, Paul and Gaujard, Sylvain and De La Gastine, Blandine and Leperre, Armelle and Chauleur, Youri and Lanfranchi, Giuseppina and Schir, Sophie and Brunet, Thomas and Gueremy, Alexandre and Bosch, Alexie and Destrem, Anne-Laure and Isnard, Margaux},
	month = nov,
	year = {2025},
	pages = {dkaf381},
}
Downloads: 1
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021